NCT06557720 Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology
| NCT ID | NCT06557720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Drug Resistant Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-06-11 |
| Primary Completion | 2027-06-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-06-11 with a primary completion date of 2027-06-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Using multimodal imaging technology, this study aims to explore the characteristics of epileptogenic foci in patients with drug-resistant epilepsy and identify key network nodes (such as central nodes) to provide more assistance for the diagnosis of drug-resistant epilepsy.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥18 years old; 2. Meet the 2010 International League Against Epilepsy (ILAE) diagnostic criteria for drug-resistant epilepsy; 3. Duration of epilepsy ≥2 years, with an average seizure frequency of ≥2 times per month in the 3 months prior to enrollment; 4. Adequate intake of two or more anti-epileptic drugs, with no intervention in the treatment plan during the trial period; 5. Capable of cooperating to complete treatment and related examination items; The patient and family fully understand and voluntarily sign the informed consent form. Exclusion Criteria: 1. In a state of continuous epileptic seizures; 2. Complicated with severe infections, cerebrovascular diseases, malignant tumors, and other diseases, accompanied by severe dysfunction of the heart, liver, kidney, or other organs, or with mental disorders, or with uncorrectable hyperglycemia, or 3.patients on long-term use of corticosteroid medications; 4.Pregnant or lactating women; 5.Contraindications for PET, MR, EEG examinations; 6.Patients with examinations (with ferromagnetic metal implants in the body; high fever); 7.Participating in other clinical trials at the same time; 8.The patient or family withdraws the informed consent form.
Contact & Investigator
Jiang Wen
STUDY CHAIR
Xi Jing hospital
Frequently Asked Questions
Who can join the NCT06557720 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Drug Resistant Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06557720 currently recruiting?
Yes, NCT06557720 is actively recruiting participants. Contact the research team at guanxiao0223@163.com for enrollment information.
Where is the NCT06557720 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06557720 clinical trial?
NCT06557720 is sponsored by Xijing Hospital. The principal investigator is Jiang Wen at Xi Jing hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.